A study published by BloodAdvances, a Journal of the American Society of Hematology, demonstrated the potential of the 2-pronged approach in treating non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia.
A study published by BloodAdvances, a Journal of the American Society of Hematology, demonstrated the potential of the 2-pronged approach in treating non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia.
New research from the study suggested that blood cancer may be effectively treated with a 2-pronged approach. This new approach involves directly attacking cancer cells in addition to redirecting them from bone marrow into the peripheral blood streams. When cancer cells are in the blood stream, there are more treatment options as the cells are more vulnerable to treatments like chemotherapy.
Flavia Pernasetti, PhD, of Pfizer Oncology Research and Development worked with her team to develop an antibody, PF-06747143, that has demonstrated the ability to preclinically attack and kill the cells while moving the cells away from their protective environment in bone marrow.
“One of the major limitations we see in treating blood cancers is the failure to clear cancer cells from the bone marrow,” Pernasetti said in a statement. “Because the bone marrow allows the cancer cells to flourish, removing these cells is an essential step in treating these malignancies effectively. Not only does our approach have the potential to get these cells out of the marrow, making them more susceptible to standards of care, it is designed to also directly attacks the cancer cells."
While testing the efficacy of the antibody, researchers used it alone and along with standard chemotherapy. In both cases, the antibody treatment destroyed more cells than the typical blood cancer treatments. More specifically, when treating acute myeloid leukemia, utilization of the antibody alone resulted in a 95.9% decrease in cancer cells. When the antibody was combined with the standard chemotherapy agents, daunorubicin and cytarabine, 99.7% of cancer cells were killed.
“Our preliminary preclinical results are encouraging, and we are very excited to see how our antibody fares in clinical testing," said Pernasetti.
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More